Breakthrough Blood Test Spots Deadly Cancer Sooner

A novel blood test, PANXEON, has demonstrated notable success in detecting early-stage pancreatic cancer, offering a promising advancement for diagnostics. Researchers have developed this test by combining three biological markers with artificial intelligence to create a single score indicating the likelihood of cancer.

The study, published in Nature Medicine on September 16, involved nearly 1,800 participants from the U.S., Europe, and Asia. PANXEON correctly identified patients with stage 1 and 2 pancreatic cancer in 87% of cases, with a low false-positive rate. It also detected advanced precancerous lesions in about 64% of cases, suggesting potential for identifying dangerous disease before invasive cancer develops.

Experts believe this test could serve as a crucial triage tool for individuals at increased risk, potentially helping clinicians determine which patients require earlier imaging or more intensive follow-up. While not replacing current imaging techniques like MRIs, PANXEON's ability to shift diagnoses to earlier stages, or even precancerous stages, could significantly improve treatment opportunities and patient outcomes for a cancer that is notoriously difficult to detect early.

Pancreatic cancer is one of the deadliest cancers, with over 67,000 diagnoses annually in the U.S. alone. Its deep-seated location makes early detection challenging, often leading to diagnoses only after the cancer has advanced and spread. The development of PANXEON offers hope for earlier intervention, which is critical as surgery remains the only potential cure, and currently, only about 15% of patients are eligible.